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Tat stimulates HIV-1 gene expression during transcription initiation and elongation. Tat functions primarily through specific
interactions with TAR RNA and several putative cellular cofactors to increase the processivity of RNA polymerase II complexes
during HIV-1 transcription elongation. Although HIV-1 transactivation by Tat in most cell types requires intact TAR sequences,
previous reports demonstrate that Tat transactivates HIV-1 long terminal repeat (LTR)-directed gene expression in several
central nervous system-derived astrocytic/glial cell lines in the absence of TAR. Within this study, transient expression assays
performed in the astrocytic/glial cell line, U87-MG, confirm that kB elements within the HIV-1 LTR mediate TAR-independent
transactivation by Tat and demonstrate additionally that distinct amino acid residues within the cysteine-rich activation domain
of Tat are required for TAR-independent versus TAR-dependent transactivation. Established U87-MG cell lines expressing a
transdominant negative mutant of IkBa, IkBaDN, fail to support TAR-independent transactivation by Tat, suggesting that
binding of NF-kB to kB enhancer elements within the HIV-1 LTR is necessary for Tat-mediated transactivation in the absence
of TAR. Ribonucleic acid protection analyses of promoter-proximal and -distal transcripts derived from TAR-deleted and TAR-
containing HIV-1 LTR reporter constructs in U87-MG cells indicate that the predominant effect of Tat during TAR-independent
transactivation occurs at the level of transcription initiation, whereas a prominent elongation effect of Tat is observed in the
presence of TAR. These data suggest an alternative regulatory pathway for Tat transactivation in specific cells derived from
the central nervous system that is independent of TAR and that requires direct or indirect interaction of Tat with NF-kB-
binding sites in the HIV-1 LTR. q 1997 Academic Press
INTRODUCTION and/or indirect effects of both viral and cellular factors in
different populations of CNS-derived cells (Lipton, 1994;
Central nervous system (CNS) dysfunction is often Lynn and Wong, 1995).
found in association with human immunodeficiency virus Although several cell types in the brain may be infected
type-1 (HIV-1) infection, yet the pathogenic mechanisms in vivo and in vitro (Cheng-Meyer et al., 1987; Brack-
of acquired immunodeficiency syndrome (AIDS)-related Werner et al., 1992; Moses et al., 1993; Tornatore et al.,
CNS disorders are poorly understood. HIV-1 can be re- 1994a,b; Nuovo et al., 1994), high titers of HIV-1 are found
covered from brain tissue, spinal fluid, spinal cord, and predominantly in microglial cells and macrophages of the
peripheral nerves of patients with neurological complica- brain. Macroglial cells consisting of oligodendrocytes,
tions of AIDS. Additionally, HIV RNA has been detected ependymal cells, and astrocytes, a type of glial cell that
in microglial nodules in the brain. HIV-1 proviral DNA sustains neurons, can be infected with HIV-1 in vitro
appears to be more abundant in the brains than in lymph and in vivo (Cheng-Meyer et al., 1987; Price et al., 1988;
nodes or spleens of some infected individuals. Cellular Tornatore et al., 1991, 1994a,b; Brack-Werner et al., 1992;
damage in the CNS is found in 80 to 90% of the people Nath et al., 1995; Geiger and Sarvetnick, 1995). The
who die with AIDS and preeminently has become 1 of astrocytic/glial cells have putative direct and/or indirect
the top 10 causes of death in pediatric AIDS patients roles in HIV-1-associated neuropathogenesis (Merrill
(Johnson, 1995; Merrill and Jonakait, 1995). Decreased and Chen, 1991; Genis et al., 1992; Epstein and Gendel-
brain weight with loss of neurons, encephalitis, cortico- man, 1993; Bensons et al., 1994; Blumberg et al., 1994;
spinal tract degeneration, and gliosis are among the di- Nuovo et al., 1994) and support low levels of viral replica-
verse neuropathological findings in HIV-1-infected indi- tion in vivo (Blumberg et al., 1994; Nuovo et al., 1994;
viduals (Tornatore et al., 1994a,b; Merrill and Jonakait, Tornatore et al., 1994a,b).
1995; Lynn and Wong, 1995). Several studies suggest The HIV-1-encoded regulatory protein, Tat, may play a
that HIV-1-associated neuropathogenesis may involve direct or indirect role in CNS dysfunction in HIV-1-in-
several complex regulatory pathways that elicit direct fected individuals. In the CNS, biologically active Tat,
released from HIV-1-infected cells, may be taken up from
the extracellular environment by neuronal cells to exert1 To whom reprint requests should be addressed. Fax: (504) 587-
7389. E-mail: cmorris@tmc.tulane.edu. its transactivational activity (Kolson et al., 1994). Secreted
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Tat protein increases leukocyte adhesion and alters element be maintained, presumably facilitating Sp1 and
TBP interaction (Huang et al., 1993; Emili et al., 1994).blood–brain barrier permeability to enhance dissemina-
tion of HIV-1-infected cells into the CNS (Hofman et al., Moreover, NF-kB cooperates with Sp1 to enhance tran-
scriptional activity (Perkins et al., 1993) and Tat syner-1994). Recombinant Tat protein significantly increases
mRNA levels of fibronectin and collagen types 1 and gizes with Sp1 and NF-kB to activate HIV-1 LTR-directed
gene expression (Kamine and Chinnadurai, 1992; Liu et3, components of the extracellular matrix that mediate
extravascular dissemination of HIV-1 in human glial cells al., 1992; Sune and Garcia-Blanco, 1995). Recently, evi-
dence has shown that the basic domain of Tat directly(Taylor et al., 1992a). Additionally, Tat stimulates trans-
forming growth factor-b1 (TGF-b1), a cytokine that exhib- interacts with RNA polymerase II to increase HIV-1 LTR
gene expression (Wu-Baer et al., 1995; Mavankal et al.,its potent immunosuppressive activity in CNS-derived
glial cells (Cupp et al., 1993). The RGD domain of Tat 1996). Also, Tat specifically associates with TAK, a cellu-
lar kinase which phosphorylates the C-terminal domainmediates markedly induced aggregation of neurons and
astrocytes in primary brain cell cultures, potentiating pu- (CTD) of RNA polymerase II (Herrman and Rice, 1995).
Accordingly, TAR-dependent transcriptional transactiva-tative changes in normal cellular organization within the
brain (Kolson et al., 1993). Additionally, Tat acts as a tion by Tat in vivo and in vitro requires the CTD of RNA
polymerase II (Okamoto et al., 1996). Activated HIV-1potent neurotoxin, resulting in CNS damage that is medi-
ated through its basic region (amino acid residues 49 to transcriptional elongation by Tat in vitro requires both
TFIIH and the CTD of RNA polymerase II (Parada and57) (Sabatier et al., 1991; Hayman et al., 1993; Philippon
et al., 1994). An overlapping region of Tat spanning amino Roeder, 1996). Tat, through its activation domain, inter-
acts with transcription initiation complexes containingacid residues 31 to 61 mediates increases in intracellular
calcium and neurotoxicity, causing excitation of neurons TFIIH and stimulates TFIIH-mediated CTD phosphoryla-
tion (Parada and Roeder, 1996). These latter effects of(Nath et al., 1996). Collectively, these findings suggest
that Tat may affect neuropathogenesis by several differ- Tat require initiation of HIV-1 RNA synthesis.
Several studies suggest that Tat transactivates HIV-1ent mechanisms.
Tat is a potent transactivator of HIV-1 gene expression gene expression in the absence of TAR. The molecular
mechanisms of both TAR-dependent and TAR-indepen-and replication that significantly increases the rate and/
or efficiency of HIV-1 transcription initiation and elonga- dent transactivation are not fully known. TAR-independent
transactivation of HIV-1 by Tat has been demonstratedtion (Laspia et al., 1989, 1993; Marciniak et al., 1990a;
Marciniak and Sharp, 1991; Adams et al., 1994; Rittner essentially by two different approaches. In the first, the
activation domain of Tat is fused to heterologous proteinset al., 1995). Tat transactivates HIV-1 LTR-directed gene
expression through direct interaction with the TAR ele- that mediate nucleic acid binding to tether Tat promoter-
proximally to the HIV-1 LTR in the absence of TAR viament, located within nascent HIV-1 mRNA leader se-
quences between /14 and /44 relative to the transcrip- heterologous protein-binding sites. For example, a Tat–
Jun fusion protein is able to activate gene expressiontion initiation start site at /1. The 3-bp bulge between
/23 and /25 within the TAR RNA stem–loop secondary when bound to a HIV-1 LTR containing AP-1 binding sites
and lacking TAR (Berkhout et al., 1990). Similar experi-structure is required for Tat transactivation and Tat bind-
ing, and the 6-bp loop between /30 and /35 is neces- ments demonstrate that a Gal4 Tat fusion protein activates
HIV-1 LTR-directed gene expression in the absence ofsary for binding of the cellular protein TRP-185 (Feng and
Holland, 1988; Garcia et al., 1989; Berkhout et al., 1989; TAR when Gal4 DNA-binding sites are positioned at the
5* end of the promoter (Southgate and Green, 1991). OtherDingwall et al., 1989; Roy et al., 1990; Calnan et al., 1991;
Wu et al., 1991; Sheline et al., 1991). chimeric proteins containing Tat fused to a RNA-binding
protein (e.g., Rev, MS2) transactivate a HIV-1 LTR in whichAlthough TAR sequences are important in mediating
Tat activity, several cis-acting regulatory elements in the the TAR element is substituted with either the Rev-respon-
sive element or the RNA-binding sites of the MS2 bacterio-HIV-1 LTR are essential as well; these elements include
the proximal enhancer element, containing two NF-kB- phage coat protein (Selby and Peterlin, 1990; Southgate
et al., 1990). The second approach to demonstrate TAR-binding motifs (Nabel and Baltimore, 1987), and the core
element, containing three Sp1-binding sites (Harrich et independent HIV-1 transactivation by Tat has been possi-
ble due to the unique cell specificity of this phenomenon.al., 1989; Kamine et al., 1991; Kamine and Chinnadurai,
1992), a TATA element (Garcia et al., 1989; Berkhout and More precisely, TAR-independent activation of HIV-1 tran-
scription by Tat is observed in phorbol ester-stimulated TJeang, 1992; Lu et al., 1993), and an initiator element
(Zenzie-Gregory et al., 1993). Binding of Tat to the TATA- lymphocytes and in central nervous system-derived glial
cells where, in both instances, kB-responsive elementsbinding protein (TBP) in vitro (Kashanchi et al., 1994;
Veschambre et al., 1995; Wang et al., 1996) and to Sp1 are absolutely required (Harrich et al., 1990; Bagasra et
al., 1992; Taylor et al., 1992a, 1993, 1994, 1995). Further,in vivo and in vitro (Jeang et al., 1993) suggests the signifi-
cance of these upstream elements in Tat transactivation. recent evidence suggests that Tat binds to an adapter
molecule found abundantly in astrocytic cells and stimu-Maximal transactivation by Tat requires that optimal spa-
tial conformation between the Sp1 sites and the TATA lated T lymphocytes that facilitates the interaction of NF-
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kB with HIV-1 LTR transcription complexes in the absence standing the molecular mechanism(s) of HIV-1 regulation
in these cells may discern a functional role for Tat inof TAR (Taylor et al., 1995). Moreover, mutational analyses
of the activation domain of Tat strongly suggest that com- AIDS-associated neuropathogenesis.
mon cellular targets for Tat during TAR-dependent and
TAR-independent transactivation exist (Taylor et al., 1993). MATERIALS AND METHODS
As yet, the mechanism(s) of TAR-independent transactiva-
Cell culturetion of HIV-1 transcriptional initiation and/or elongation by
Tat has not been elucidated. Interestingly, Tat not only U87-MG (ATCC HTB14) and HeLa cells (ATCC CCL2)
transactivates several cellular gene promoters (e.g., TNF- were grown as monolayer cultures in Dulbecco’s modified
a, TNF-b, TGF-b1, TGF-a, IL-6, IL-2, IL-4 receptor, c-myc, Eagle’s medium supplemented with 10% fetal bovine se-
bcl-2, G6PD, fibronectin, and collagen type 1 and 3) (Puri rum (Gibco BRL), 2 mM L-glutamine, and 100 mg/ml penicil-
and Aggarwal, 1992; Taylor et al., 1992a; Cupp et al., 1993; lin/streptomycin (Gibco BRL) in a 5% CO2 incubator at 377.
Ursini et al., 1993; Buonaguro et al., 1994; Nabell et al.,
1994; Scala et al., 1994; Westendorp et al., 1994; Wright Plasmids
et al., 1994; Biswas et al., 1995; Zauli et al., 1995), but also
downregulates the MHC class I promoter (Howcroft et al., The HIV-1 LTR reporter construct, CD23, contains HIV-
1 sequences from 0117 to /84 relative to the transcrip-1993, 1995). Additionally, Tat transactivates heterologous
viral promoters (e.g., JCV, murine CMV, and HHV-6) tion initiation start site ligated upstream of the chloram-
phenicol acetyltransferase (CAT) gene (Taylor et al.,(Chowdhury et al., 1990, 1992; DiLuca et al., 1991; Kim et
al., 1993). The effects of Tat on cellular gene and heterolo- 1992a). The CD23DS construct is identical to CD23 ex-
cept for a deletion of sequences between /35 and /38gous viral promoters that lack TAR sequences illuminate
the complexity underlying the different mechanisms that (Taylor et al., 1992a). G6 0119 HIV LTR DTAR, G6 083
HIV LTR DTAR, G6 069 HIV LTR DTAR, and G6 031may influence the transregulatory functions of Tat.
HIV-1 persistently infects human astrocytes; rare viral HIV LTR DTAR constructs containing six Gal4 DNA-bind-
ing sites and lacking TAR sequences downstream ofantigen presentation is characteristic of these infected
cells (Merrill and Jonakait, 1995). The astrocyte model of position /25 have been described previously (Southgate
and Green, 1991). Wild-type and mutant Tat cDNAs, in-HIV-1 infection is fundamentally different from that within
mononuclear cells (Tornatore et al., 1994a). Recent stud- cluding Cys22, Thr23, Asn24, Tyr26, Lys2829, Cys31,
His33, Gln35, Lys41, Tyr47, and D57 from pGEM-1 ex-ies indicate that during pediatric HIV-1 infection, expres-
sion of HIV-1 regulatory proteins in astrocytes is more pression vectors (Rice and Carlotti, 1990a) were sub-
cloned into the pCMV12S.FS expression vector betweenprevalent than in adult AIDS (Saito et al., 1994; Tornatore
et al., 1994a). The role infected astrocytes play in the the EcoRI and HindIII sites, replacing E1A 12S se-
quences with Tat-specific sequences. All wild-typepathogenesis of AIDS-associated CNS disorders re-
mains unclear. In the studies presented herein, human (pCMVTat) and mutant Tat (pCMVCys22, pCMVThr23,
pCMVAsn24, pCMVTyr26, pCMVLys2829, pCMVCys31,astrocytic glial cells are used as a model system to inves-
tigate the mechanisms of TAR-independent transactiva- pCMVHis33, pCMVGln35, pCMVLys41, pCMVTyr47, and
pCMVD57) constructs were confirmed by DNA sequenc-tion of HIV-1 transcription by Tat. The results presented
(1) confirm the ability of Tat to transactivate HIV-1 LTR- ing. The expression vector pCMV12S.FS contains a
frame-shift mutation within E1A 243R coding sequencesdirected gene expression within glial cells in the absence
of TAR sequences, (2) show that Tat mediates cell-type- and is unable to generate functional E1A protein and,
thus, served as a control vector. Expression plasmidsspecific and differential effects on TAR-dependent versus
TAR-independent transactivation, (3) confirm that kB for promoter-proximal effectors, including Gal4 Sp1, Gal4
Sp1Q, Gal4 AH, Gal4 RegI, Gal4 RegII, Gal4 Vp16, andsites are required for TAR-independent transactivation
by Tat, suggesting a role for kB sites in tethering Tat to Gal4 1-94, have been described previously (Morris et
al., 1994). The expression vector, Gal4 Tat, has beenthe promoter in the absence of TAR, (4) demonstrate that
promoter-proximal effectors, including a Gal4 RelA fusion described previously (Southgate and Green, 1991).
The b-galactosidase (bgal) and IkBa retroviral con-protein, fail to fully rescue TAR-independent transactiva-
tion by Tat in glial cells, (5) show that stable expression structs were made using the pLNCX vector (Miller and
Rosman, 1989). The pLNCX bgal retroviral plasmid wasof a transdominant repressor mutant of IkBa in glial cells
inhibits TAR-independent transactivation by Tat, and (6) constructed by digesting pCMVbgal (Lockyer and
McCracken, 1991) with NotI to obtain the b-galactosidasedemonstrate that Tat activates HIV-1 LTR-directed gene
expression in glial cells in the absence of TAR predomi- gene. The fragment was then treated with Klenow to gen-
erate blunt ends and subcloned into the HpaI site ofnantly by increasing the level of transcription initiation
and in the presence of TAR predominantly by stimulating pLNCX. Orientation was determined by restriction map-
ping with ClaI. The N-terminally deleted IkBa fragmenttranscription elongation. These data suggest an alterna-
tive regulatory pathway for Tat-mediated transactivation was obtained by digesting pCMV4IkBaDN (Brockman et
al., 1995) (gift from Dean Ballard, Vanderbilt University,of HIV-1 gene expression in astrocytic glial cells. Under-
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Nashville, TN) with HindIII and SmaI. The insert was then Incubation was performed in the presence of 4 mg/ml
polybrene. Twenty-four hours after exposure to the c2subcloned into pLNCX digested with HindIII and HpaI.
The Gal4 RelA expression vector was previously de- supernatants, the PA317 cells were replated onto 100-
mm plates and selected with G418 at a concentration ofscribed (Brasier et al., 1996) and was generously pro-
vided by Dr. Allan Brasier (University of Texas Medical 750 mg/ml active G418. Colonies of virus-producing cells
were then pooled and used as a source of virus forBranch, Galveston). This vector contains the full-length
human RelA coding sequences (1–551). transduction of U87-MG cells. The viruses were titered
as described (Miller and Rosman, 1989) using NIH3T3
Transfections cells. All viruses employed for these experiments had
titers of at least 105/ml.
U87-MG cells (70% confluent) or HeLa cells (50% conflu-
ent) grown in 6-cm dishes were fed fresh medium 6 hr
Transduction of U87-MG cellsbefore transfection by standard calcium phosphate co-
precipitation techniques (Tsang et al., 1996). Optimum Viral transductions were performed as follows.
concentrations of Tat or control expression plasmids of Twenty-four hours following plating at 50% confluency,
each promoter were determined in titration experiments. U87-MG cells were exposed for 1 min to 250 mg/ml
Unless otherwise noted in the figure legends, transfection DEAE-dextran in phosphate-buffered saline. The DEAE-
mixtures were prepared as follows. Reporter plasmids, dextran was then aspirated and replaced with 1 ml of
CD23 or CD23DS (300 ng), were cotransfected with 5 mg viral supernatant in a total of 3 ml of medium. After 4 hr,
of the expression plasmids for wild-type or mutant Tat or the virus-containing medium was removed and the cells
the control vector, pCMV12S.FS. G6 0119 HIV LTR DTAR, were incubated in complete growth medium. Twenty-four
G6 083 HIV LTR DTAR, G6 069 HIV LTR DTAR, and G6 hours following viral exposure, the cells were replated
031 HIV LTR DTAR (5 mg) were cotransfected with 0.1 onto 100-mm plates and selected with G418 at a concen-
mg of pCMVTat, Gal4Tat, or pCMV12S.FS vectors. Five tration of 750 mg/ml active G418. Cells were selected for
micrograms of G6 031 HIV LTR DTAR and 5 mg of each 4 weeks prior to their use in transient expression assays.
promoter-proximal effector were cotransfected with 0.1 mg
pCMVTat or pCMV12S.FS. The total amount of DNA in all CAT assays
transfections performed was normalized to 20 mg with
Cell extracts were prepared by three successive cy-herring sperm DNA. The DNAs were mixed with 250 ml
cles of freezing (0807) and thawing (377) in 100 ml of 0.25of 21 HBS solution [1.6 g NaCl, 0.99 ml 2 M KCl, 0.025 g
M Tris–HCl (pH 8.0). CAT assays (Tsang et al., 1996)Na2HPO4 (anhydrous), 0.2 g glucose, 1.0 g HEPES in 100
were performed with various amounts of cell extractsml solution]. Then, 250 ml of 0.32 M CaCl2 was added
and incubation times at 377 to obtain results in lineardropwise into the DNA/21 HBS mix. The mixture was
range. CAT acetylation of each sample on thin-layer chro-incubated for 10 min to form a fine precipitate at room
matography was quantified with a Fuji PhosphoImagertemperature. At the end of the incubation, the precipitate
using an Image-Quant Program. CAT results were nor-was resuspended by gently pipetting up and down. The
malized to total protein within cell extracts as determinedmixture was applied to the medium of the cell monolayer,
by Bradford assays (Bio-Rad). Unless otherwise indi-then was mixed gently. Sixteen hours posttransfection, the
cated, the relative CAT activities represent the averagemedium was removed, the monolayer was washed with
of three identical transfections performed in duplicate.PBS (phosphate-buffered saline), and fresh medium was
added. Cells were harvested 42–48 hr posttransfection.
Construction of antisense riboprobes
Preparation of retroviruses
Vector pGEM3ZDTAR was constructed to provide a
means of generating an antisense RNA probe to detectRetroviruses were generated using a two-step packag-
ing protocol. The first packaging cell line, c2, was plated promoter-proximal mRNA transcripts derived from re-
porter plasmids lacking intact TAR sequences. Two prim-at a density of 150,000/60-mm plate. Eighteen hours later,
the cells were transfected with pLNCX plasmids (10 mg ers were used (5* primer, PstI-117 HIV LTR 5* CAGTCC-
TGCAGCGAGCTTGCTACAAGGGAACT 3*; 3* primer,of DNA plus 10 ml of lipofectin reagent; Gibco BRL) con-
taining the control bgal gene or the IkBa-encoding cDNA CAT63-BamHI 5* ATACGGGATCCCAACGGTGGTATA-
TCCAGTG 3* ) to PCR-amplify sequences from 0117 to(IkBDN). Five hours after treatment, the medium was
replaced with growth medium (DMEM plus 10% fetal calf downstream sequences containing 63 nt of the CAT gene
using G6 0119 HIV LTR DTAR as a template. The PCRserum). Thirty-six hours following lipofection, the medium
was harvested and used to infect the second packaging product was then digested with PstI and BamHI and
subsequently cloned into the pGEM3Z vector (Promega).cell line, PA317 cells (obtained from American Type Cul-
ture Collection, Rockville, MD). The PA317 cells were pGEM3ZDTAR was linearized with PvuII and the anti-
sense probe was transcribed at 377 for 1 hr in vitro in aplated at a density of 150,000/60-mm plate 16–18 hr prior
to exposure to the c2 supernatants (100 ml to 1 ml). reaction mix including T7 polymerase (7–10 U) (Pro-
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mega), [32P]UTP (50 mCi, 3000 Ci/mmol) (Amersham), appears to be required for TAR-dependent transactiva-
tion. Recently, two-dimensional nuclear magnetic reso-10 mM ATP, GTP, and CTP, and 0.24 mM UTP.
pGEM3ZCAT was constructed to provide a means of nance methods and molecular dynamics calculations
have unveiled the structure of HIV-1, Zaire 2 isolate, Tatgenerating an antisense RNA probe that would hybridize
specifically to promoter-distal mRNA sequences synthe- in solution. Within this structure, part of the N-terminus
is sandwiched between a hydrophobic core and a gluta-sized from the reporter constructs used in these studies.
CAT-specific sequences were derived from pcDNA3CAT mine-rich domain. In addition, two highly flexible do-
mains that correspond to the cysteine-rich and basic-(InVitrogen) by digestion with EcoRI and BamHI and sub-
cloning into the pGEM3Z vector. pGEM3ZCAT was linear- region domains are apparent (Bayer et al., 1995). Previ-
ous reports demonstrate, in astrocytic glial cells, that theized with EcoRI and the antisense probe was transcribed
at 377 for 1 hr in vitro in a reaction mix including SP6 same amino acid residues within the activation domain
of Tat are required for both TAR-independent and TAR-polymerase (7–10 U) (Promega), [32P]UTP (50 mCi,3000
Ci/mmol) (Amersham), 10 mM ATP, GTP, and CTP, and dependent transactivation of HIV-1 LTR-directed gene
expression that is unrelated to cell-type specificity. These0.24 mM UTP. For detecting promoter-proximal tran-
scripts derived from TAR-containing reporters, antisense data, based on selective mutagenic analyses of Tat, sug-
gest the existence of common cellular targets for Tatprobes were generated from pGEM23, a vector con-
taining HIV-1 LTR sequences 0117 to /83, as described during both TAR-independent and TAR-dependent trans-
activation (Taylor et al., 1993).previously (Laspia et al., 1993). All labeled RNA probes
were treated with DNase (0.5 mg/ml) at 377 for 15 min The cysteine-rich domain is highly conserved among
Tat proteins from different HIV-1 isolates and the relatedand subsequently extracted with phenol:chloroform (1:1)
and ethanol precipitated; probes were then purified from HIV-2 and SIV (Frankel et al., 1988; Kuppuswary et al.,
1989; Rice and Carlotti, 1990a). Two epitopes mapping6% polyacrylamide 8 M urea gels.
to the cysteine-rich and basic domains of HIV-1 Tat have
Ribonuclease protection assays been identified using natural anti-Tat IgM antibodies
(Rodman et al., 1993). The cysteine-rich region of TatCytoplasmic RNAs from cells cotransfected with indi-
contains a putative metal-binding motif that has beenvidual reporter constructs and either a control vector,
postulated to mediate Tat dimerization and/or intradisul-pCMV12S.FS, or an expression vector, pCMVTat, were
fide bond formation (Rosen and Pavlakis, 1990). Muta-isolated after 36 hr posttransfection and prepared follow-
tions within the cysteine-rich domain of Tat have beening lysis with Nonidet-P40, phenol:chloroform (1:1) ex-
well-characterized previously for their effects on HIV-1traction, and ethanol precipitation (Morris et al., 1994).
transactivation. In vivo transient expression assays utiliz-Subsequently, all cytoplasmic RNAs were treated with
ing these mutants demonstrate that the cysteine-rich do-DNase (0.5 mg/ml) and were recovered following phe-
main is essential for Tat transactivation in nonglial cellsnol:chloroform (1:1) extraction and ethanol precipitation.
(Rice and Carlotti, 1990a).Ten micrograms of cytoplasmic RNA was mixed with the
The initial study discerning the functional domains ofriboprobes (1 1 106 cpm) in 5 ml hybridization buffer (80%
Tat required to mediate TAR-independent transactivationformamide, 40 mM PIPES, pH 6.5, 400 mM NaCl, 1 mM
in astrocytic glial cells demonstrated analyses of a fewEDTA) and were incubated at 427 overnight. Hybridization
mutations in the cysteine-rich domain of Tat, all of whichreactions were incubated in 100 ml RNase digestion mix
affected TAR-dependent and TAR-independent transacti-(10 mM Tris–Cl, pH 7.5, 5 mM EDTA, 300 mM NaCl, 12
vation similarly (Taylor et al., 1993). To comprehensivelyU RNase T1) at 307 for 1 hr. The reactions were termi-
target specific amino acid residues within the cysteine-nated by the addition of SDS (0.5%) and proteinase K (0.1
rich activation domain of Tat that are required for TAR-mg/ml) and incubation at 377 for 15 min. Duplex RNA
independent and TAR-dependent transactivation in glialhybrids were extracted with phenol:chloroform (1:1), eth-
cells, an extensive panel of site-directed mutations withinanol precipitated, and resolved by electrophoresis
the cysteine-rich region of Tat (Fig. 1) was examined inthrough 6% polyacrylamide 8 M urea sequencing gels.
transient expression assays. TAR-containing and TAR-Protected fragments were detected and quantified by
deleted HIV-1 LTR CAT reporter constructs, CD23 andFuji PhosphoImaging and by autoradiography using an
CD23DS, were cotransfected with wild-type or mutantintensifying screen at 0807.
Tat expression vectors or with a control expression vec-
tor, pCMV12S.FS. Relative CAT activities from cellularRESULTS
extracts were determined 42–48 hr posttransfection. The
Site-directed mutations within the cysteine-rich results demonstrated that wild-type Tat stimulates TAR-
domain of HIV-1 Tat mediate differential effects on independent transactivation in glial cells as indicated by
TAR-independent and TAR-dependent transactivation a fivefold increase in CAT activity relative to basal levels
in a cell-type-specific manner observed in the absence of Tat (pCMV12S.FS) (Fig. 2).
TAR-independent transactivation was significantly re-HIV-1 Tat protein contains an acidic-rich, a cysteine-
rich, and a basic-rich functional domain, each of which duced when a glycine or alanine substitution was made
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TABLE 1
TAR-Independent and TAR-Dependent Transactivational Activities
of Wild-Type and Mutant Tat in Glial Cells (U87-MG Cells) and Non-
glial cells (HeLa Cells)
Relative CAT activities
U87/CD23DS U87/CD23 HeLa/CS23
WT 1 1 1
Cys22 0.49 { 0.18 0.76 { 0.24 0.17 { 0.02
Thr23 2.82 { 0.65 1.02 { 0.06 1.71 { 0.12
Asn24 2.25 { 0.27 1.09 { 0.04 1.88 { 0.94
Tyr26 1.77 { 0.72 0.42 { 0.06 0.05 { 0.04
Lys2829 1.49 { 0.17 1.06 { 0.06 0.08 { 0.06
Cys31 2.61 { 0.82 1.16 { 0.18 0.62 { 0.22
His33 1.77 { 0.77 0.90 { 0.25 0.25 { 0.13
Gln35 0.26 { 0.10 0.84 { 0.19 0.18 { 0.13FIG. 1. Schematic representation of wild-type and mutant Tat pro-
Lys41 1.32 { 0.48 0.95 { 0.20 0.30 { 0.07teins. Wild-type Tat contains a RNA-binding domain and an activation
Tyr47 2.19 { 0.52 1.09 { 0.08 3.10 { 1.00domain including acidic-rich, cysteine-rich, and core-region domains.
D57 2.30 { 0.63 1.07 { 0.14 NDAmino acid residues are numerically shown. Mutant Tat proteins are
indicated with arrows. Each mutant is designated by the wild-type
Note. HIV LTR CAT reporter constructs (300 ng) containing (CD23)amino acid that is changed and its amino acid position. Glycine is
or lacking (CD23DS) intact TAR sequences were contransfected withsubstituted for Cys22 and Cys31. Other mutants, including Thr23,
wild-type or mutant Tat-expressing vectors (5 mg) with a control expres-Asn24, Tyr26, Lys2829, His30, Gln35, Lys41, and Tyr47, were substi-
sion vector (5 mg) into U87-MG cells or HeLa cells as described undertuted with alanine.
Materials and Methods. The relative CAT activities, representing aver-
aged values from three identical transfections performed in duplicate,
in the cysteine 22 or glutamine 35 residues of Tat, re- were determined by calculating the ratio of promoter activity in the
presence of each Tat expression plasmid relative to that observed inspectively (Table 1). In comparison, only the Tyr26 Tat
the presence of the control expression plasmid, pCMV12S.FS. Ratiosmutant demonstrated reduced CAT activity relative to that
of relative CAT activities of wild-type Tat to 12S.FS for each promoterof wild-type Tat in the presence of TAR (Table 1). Other
in the different cell types were set, arbitrarily, at a value of 1. Ratios
Tat mutants demonstrated CAT activities greater than of relative CAT activities of each mutant Tat to 12S.FS were calculated
or equivalent to that observed with wild-type Tat in the relative to that demonstrated for wild-type Tat. Calculated values for
standard error of mean are indicated. ND, not determined.
presence or absence of TAR in glial cells (Table 1). As
predicted from previous characterization studies of these
cysteine-rich domain mutations (Rice and Carlotti,
1990a), most mutations severely inhibited TAR-depen-
dent transactivation in HeLa cells (Table 1).
These results (1) confirm TAR-independent transacti-
vation by HIV-1 Tat in glial cells, (2) demonstrate that
distinct amino acid residues differentially modulate TAR-
dependent versus TAR-independent transactivation in
glial cells, and (3) show that mutations in Tat that signifi-
cantly reduce TAR-dependent transactivation in HeLa
cells fail to inhibit TAR-dependent transactivation in glial
cells, implying that the molecular mechanisms operative
during transactivation of HIV-1 gene expression are cell-
type specific.
Enhancer sequences spanning the kB sites within theFIG. 2. Effects of Tat on HIV-1 LTR activity in the absence of TAR in
U87-MG cells. U87-MG cells were cotransfected with G6-119 HIV LTR HIV LTR mediate TAR-independent transactivation by
DTAR CAT (5 mg) in the presence of a wild-type Tat expression vector Tat in glial cells
(pCMVTat; 0.1 mg) or a control expression vector (pCMV12S.FS; 0.1
mg). Fold transactivation was determined by calculating the amount of Previous data demonstrated that TAR-independent
CAT conversion for the wild-type Tat expression vector over that for HIV-1 replication in astrocytic cells requires intact NF-
the control expression vector, arbitrarily set at a value of 1. Fold trans-
kB moiety-binding motifs in the HIV-1 LTR (Bagasra etactivation was determined by averaging relative CAT activities from
al., 1992). Further, results from transient expressionthree identical transfection experiments performed in duplicate. Error
bars indicate calculated values for SEM. assays in astrocytic glial cells suggested that these kB
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FIG. 3. Schematic representation of 5*-truncated HIV-1 LTR DTAR CAT reporter constructs. The wild-type HIV LTR DTAR reporter construct
contains six Gal4 DNA-binding sites (G6), two NF-kB-binding sites (0105 to 082), three Sp1-binding sites (077 to 046), a TATA box (028 to 024),
and downstream sequences (/1 to /25) positioned immediately 5* to the CAT coding sequences. Deletion of HIV-1 LTR sequences downstream
of /25 relative to the transcription initiation start site (/1) effectively destroys TAR. Each 5* truncation is indicated schematically relative to G6
0119 HIV LTR DTAR.
sites mediate Tat responsiveness in the absence of TAR Tat that binds the HIV-1 LTR indirectly through Gal4 DNA-
binding sites (Fig. 4). However, further deletion of se-(Taylor et al., 1992a). Gel mobility shift analyses of kB-
binding complexes suggested additionally that astrocyte- quences upstream of 069 (third Sp1 site) significantly
reduced Gal4 Tat activity (Fig. 4). These data suggestedderived kB-binding factors differ from prototypical NF-
kB complexes derived from Jurkat T cells. Subsequent that maximal transactivation by promoter-bound Tat in
the absence of TAR requires sequences inclusive of theobservations showed that an astrocyte-enriched activity
mediates Tat binding to the kB-binding complex (Taylor Sp1-binding sites. Gal4 Tat studies performed in nonglial
cells (data not shown and Southgate and Green, 1991)et al., 1992a, 1995). To confirm that TAR-independent
transactivation by Tat in glial cells is mediated through indicated, similarly, that Sp1 sites as well as basal pro-
moter elements (i.e., TATA) are required for transactiva-the kB enhancer elements in the HIV-1 LTR and to sug-
gest indirectly a role for kB elements in tethering Tat to tion of Tat in the absence or presence of TAR. Several
previous reports demonstrated a direct interaction ofa promoter-proximal location in the LTR, 5*-truncated HIV
LTR DTAR reporter constructs containing six Gal4-bind- HIV-1 Tat with the human TBP (Kashanchi et al., 1994;
Veschambre et al., 1995; Wang et al., 1996) and Sp1ing sites at their 5* end (Fig. 3) were cotransfected with
expression vectors for wild-type Tat or Gal4 Tat or with (Jeang et al., 1993). From the studies presented here, a
putative role for NF-kB-binding sites during TAR-inde-a control vector (CMV12S.FS) in U87-MG cells (Fig. 4).
As observed earlier, wild-type Tat transactivated the full- pendent transactivation by Tat in glial cells may be to
indirectly or directly tether Tat to the promoter.length HIV LTR DTAR, which includes two NF-kB-binding
sites, three Sp1-binding sites, and a canonical TATA ele-
Gal4 effectors fail to fully rescue Tat-mediated TAR-ment, up to 5-fold (Fig. 4). Deletion of upstream elements
independent transactivation of a minimal HIV-1between 0119 and 083, including two NF-kB-binding
promoter lacking TAR in astrocytic glial cellssites, inhibited TAR-independent Tat transactivation (Fig.
4). These data suggested that sequences spanning the Previous evidence has shown that the sequences sur-
kB enhancer elements were required for Tat transactiva- rounding (E box motifs, IST sequences) and including
tion in the absence of TAR, a finding that was confirmed the HIV-1 LTR TATA and initiator elements are involved
by work performed concurrently by independent investi- in HIV-1 transcriptional regulation (Ratnasabapathy et al.,
gators (Niikura et al., 1996). Notably, basal CAT activity 1990; Sheldon et al., 1993; Ignatius Ou et al., 1994). Re-
from HIV LTR DTAR was significantly reduced (10-fold) sults above demonstrated that deletion of sequences
when sequences upstream of 083 were deleted (not between 0119 and 083 abolished Tat transactivation in
shown). the absence of TAR (Fig. 4) and reduced basal HIV-1
Deletion of sequences upstream of 083 increased transcriptional activity approximately 10-fold in U87-MG
cells (not shown). To confirm that loss of TAR-indepen-(threefold) transactivation of HIV LTR DTAR by Gal4
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Tat was observed (Fig. 5A). The lack of transactivation
by Tat was not due to low minimal promoter activity as
basal levels of transcription were readily apparent as
indicated by a five-fold increase in basal CAT activity in
the presence of the Sp1 effectors (data not shown).
To determine whether acidic-rich effectors restore re-
sponsiveness of a minimal HIV-1 promoter to TAR-inde-
pendent transactivation by Tat, several Gal4 effector fu-
sion proteins containing activation domains of varying
strengths were tested in transient expression assays as
described above. The Gal4 effectors used in these stud-
ies included Gal4 1-94, which binds to DNA but does
not activate transcription (control); Gal4 AH, an artificial
amphipathic, transcriptional activation domain con-
taining acidic residues aligned along one face of an a-
helix; Gal4 RegI, containing Region I from the Gal4 acidic
transcriptional activation domain (amino acids 148 to
238); Gal4 RegII, containing Region II (amino acids 768–
FIG. 4. Responsiveness of 5*-truncated G6 HIV LTR DTAR reporter 881) from the Gal4 acidic transcriptional activation do-
constructs to wild-type Tat and Gal4 Tat-mediated activation. U87-MG
main (Martin et al., 1990; Morris et al., 1994); and Gal4cells were cotransfected with each of the depicted 5*-truncated HIV
Vp16, containing the strong acidic activation domain ofLTR DTAR CAT reporter constructs (5 mg) in the presence of a wild-
type Tat expression vector (pCMVTat; 0.1 mg) or a Gal4 Tat expression the herpes simplex virus Vp16 (Sadowski et al., 1988).
vector (pCMVGal4 Tat; 0.1 mg) or a control expression vector The acidic activation domains within the effector fusion
(pCMV12S.FS; 0.1 mg). Fold transactivation was determined by calculat- proteins possessed increasing activational strengths
ing the amount of CAT conversion for each wild-type Tat expression
(Gal4 VP16  Gal4 RegII  Gal4 RegI  Gal4 AH; datavector or Gal4 Tat expression vector over that for the control expression
not shown and see Morris et al., 1994). Results fromvector, arbitrarily set at a value of 1. Fold transactivation was deter-
mined by averaging relative CAT activities from three identical transfec- transient expression assays revealed that none of these
tion experiments performed in duplicated. Error bars indicate calculated Gal4 effector fusion proteins restored wild-type levels of
values for SEM. TAR-independent transactivation (fivefold) by Tat, al-
though Gal4 RegII mediated transactivation (two- to
threefold) of G6 031 HIV LTR DTAR in the presencedent transactivation by Tat in U87-MG cells was not at-
tributable simply to an overall loss of promoter activity of Tat. These promoter-proximal effector studies further
suggested the absolute requirement of kB elementsand to determine whether heterologous activation do-
mains fused to Gal4 DNA-binding domains restore TAR- within the HIV-1 LTR for TAR-independent transactivation
by Tat in glial cells.independent transactivation to a minimal HIV-1 LTR, a
minimal HIV-1 LTR CAT reporter construct containing six To determine whether RelA (p65), a member of the NF-
kB multiprotein complex that binds DNA as homodimersupstream Gal4-binding sites and lacking TAR (G6 031
HIV LTR DTAR CAT; Southgate and Green, 1991), was or as heterodimers with other NF-kB family members
such as NF-kB1 (p50) or NF-kB2 (p49) (Baeuerle, 1991),tested for its responsiveness to activation by wild-type
Tat in the presence of one of several Gal4 effectors in may affect Tat transactivation in U87-MG cells in the
absence of kB and TAR sequences, a Gal4 RelA (1–551)transient expression assays.
Several reports have shown that Tat cooperates with expression vector or a control expression vector (Gal4
1–94) was cotransfected into U87-MG cells with G6 083the cellular transcription factor Sp1 to activate HIV-1 LTR-
directed gene expression (Southgate and Green, 1991, HIV LTR DTAR or G6031 HIV LTR DTAR in the presence
(CMVTat) or absence (CMV12S.FS) of Tat. Results from1995; Berkhout and Jeang, 1992; Perkins et al., 1993;
Jeang et al., 1993; Huang et al., 1993); hence, this effector CAT assays performed 48 hr posttransfection demon-
strated that Gal4 RelA was unable to restore Tat respon-may putatively serve as a mediator of TAR-independent
transactivation by Tat in U87-MG cells. Results from tran- siveness to either reporter (Fig. 5B). The lack of Tat re-
sponsiveness in the presence of Gal4 RelA was not ap-sient expression assays testing the minimal G6 031 HIV
LTR DTAR and either Gal4 Sp1, containing the Sp1 acti- parently due to exclusive cytoplasmic sequestration of
Gal4 RelA via its IkB-binding domain or to inactivity ofvation region A (encoding amino acids 83 to 621) includ-
ing a Ser/Thr-rich region and a Gln-rich region, or Gal4 the effector as basal promoter activity increased 8-fold
(G6 083 HIV LTR DTAR) and 33-fold (G6 031 HIV LTRSp1Q, containing the Gln-rich activation region B (encod-
ing amino acids 339 to 500), in the absence or presence DTAR) in the presence of Gal4 RelA. These data collec-
tively demonstrate that the Gal4 effectors tested fail toof Tat in U87-MG cells failed to demonstrate such a role
for Sp1 during TAR-independent transactivation in these restore TAR-independent transactivation of the HIV LTR
by Tat in the absence of kB sequences, regardless ofcells as no increase in CAT activity in the presence of
AID VY 8672 / 6a3e$$$363 07-22-97 08:14:53 viral AP: VY
56 YANG ET AL.
FIG. 5. (A) Effect of Tat on minimal HIV-1 promoter lacking TAR in the presence or absence of various effectors. G6 031 HIV LTR DTAR CAT (5
mg) and the indicated Gal4 effectors (5 mg), wild-type Tat (pCMVTat; 0.1 mg) or control expression vector (pCMV12S.FS; 0.1 mg), were cotransfected
into U87-MG cells as described under Materials and Methods. Fold transactivation was determined by calculating relative CAT activities representing
the ratio of promoter activity in the presence of Tat expression plasmid relative to that observed in the presence of the control expression plasmid,
pCMV12S.FS, set at a value of 1. Each effector, Gal4 1-94, Gal4 Sp1, Gal4 Sp1Q, Gal4 AH, Gal4 RegI, Gal4 RegII, and Gal4 Vp16, increased basal
G6 031 HIV LTR DTAR activity by 2.9-, 5.0-, 3.0-, 1.3-,11.3-, 13.7-, and 295.0-fold, respectively. Error bars indicate calculated values for SEM. All
quantitative analyses of CAT assay results are represented as the averaged values generated from three separate transfections performed in
duplicate. (B) Effect of Tat on HIV-1 promoters lacking TAR and kB sites in the presence or absence of Gal4 RelA. G6 083 HIV LTR DTAR CAT (5
mg) or G6 031 HIV LTR DTAR CAT (5 mg) and Gal4 1-94 (5 mg; control) or Gal4 RelA (5 mg) were cotransfected into U87-MG cells as described
under Materials and Methods in the presence (pCMVTat; 0.1 mg) or absence (pCMV12S.FS; 0.1 mg) of Tat. Percentage CAT acetylation values for
basal and induced promoter activity are shown. Representative results shown are derived from a single transfection performed in duplicate.
whether or not Sp1 sites are present. No conclusions Tat. CAT activity from cellular extracts was determined 48
hr posttransfection. Electrophoretic mobility shift assaysmay be drawn from the Gal4 RelA experiments to deter-
mine a role for NF-kB during TAR-independent transacti- (not shown) were performed to confirm that IkBaDN ex-
pression in unstimulated or PMA-stimulated cells inhib-vation; clearly, none of the Gal4 effectors could substitute
for the presence of kB sites to mediate TAR-independent ited kB-specific binding. Results from transient expres-
sion assays demonstrated that Tat transactivated HIVtransactivation by Tat.
LTR DTAR-directed CAT expression in both untrans-
duced and bgal-transformed U87-MG cells, but not inAn IkBa-regulated NF-kB complex mediates TAR-
cells stably expressing IkBaDN (Fig. 6). Loss of TAR-independent transactivation by Tat
independent transactivation by Tat in IkBaDN-express-
IkBa is a labile cytoplasmic inhibitor of NF-kB that ing cells was not attributable to complete inhibition of
is rapidly phosphorylated and degraded in response to basal promoter activity as CAT acetylation was readily
various NF-kB-inducing agents such as proinflammatory and reproducibly quantifiable, although reduced com-
cytokines and mitogens (Baeuerle and Baltimore, 1988; pared to that observed in untransduced or control cells.
Lenardo and Baltimore, 1989). A mutant form of IkBa that
lacks the N-terminal 36 amino acid residues expresses Tat transactivates HIV-1 LTR-directed gene
a constitutive dominant-negative phenotype character- expression in the absence of TAR by increasing
ized by stable cytoplasmic association with NF-kB and the level of transcription initiation
escape from proteolytic degradation (Brockman et al.,
1995). To determine whether NF-kB complexes that are Previous in vitro studies suggest that Tat facilitates
HIV-1 transcription preinitiation complex formation andregulated by IkBa and that bind kB elements within the
HIV LTR mediate TAR-independent transactivation by Tat, effectively increases the efficiency of elongation (Bohan
et al., 1992). Although in vivo studies support a role forU87-MG cells were transduced with recombinant retrovi-
ruses expressing the N-terminally deleted form of IkBa Tat in increasing transcriptional initiation and stabilizing
elongation (Laspia et al., 1989), the predominant stimula-(IkBaDN) or bgal (control) and pooled transformants
were subsequently transfected with the 0119 HIV LTR tory effect of Tat observed in vitro is during elongation
(Laspia et al., 1993; Marciniak et al., 1990a). However,DTAR reporter plasmid containing intact kB sequences
in the presence (pCMVTat) or absence (pCMV12S.FS) of Tat stimulates transcription initiation when Tat is fused
AID VY 8672 / 6a3e$$$364 07-22-97 08:14:53 viral AP: VY
57TAT TRANSACTIVATION IN CNS-DERIVED GLIAL CELLS
ing increases in both transcription initiation and elonga-
tion in response to Tat. However, ratios of amounts of
promoter-distal to promoter-proximal transcripts gener-
ated from G6 0119 HIV LTR DTAR decreased in the
presence of Tat (0.70; lane 2) or Gal4 Tat (0.76; lane 3)
compared to a basal transcript ratio of 1 (lane 1). Al-
though Tat and Gal4 Tat may function at both transcrip-
tion initiation and elongation to activate expression from
a TAR-deleted HIV LTR containing intact NF-kB binding
sites in U87-MG cells, the greater abundance of pro-
moter-proximal transcripts relative to promoter-distal
transcripts in the presence of Tat suggested that the
predominant overall effect of Tat occurred at the level of
transcription initiation.
FIG. 6. Inhibition of TAR-independent transactivation by Tat in U87- Deletion of sequences upstream of 083 within HIV
MG cells by constitutive expression of a transdominant repressor mu- LTR DTAR and inclusive of the NF-kB-binding sites re-
tant of IkBa. U87-MG cells or stably transduced U87-MG cells express-
sulted in a loss of TAR-independent transactivation ofing bgal (control) or IkBaDN were cotransfected with 0119 HIV LTR
both promoter-proximal and promoter-distal transcriptionDTAR CAT (300 ng) in the presence (pCMVTAT: 5mg) or absence
(pCMV12S.FS; 5 mg) of Tat. Percentage CAT activity was determined by Tat (Fig. 7B; lane 5). In contrast, cotransfection of G6
from cellular extracts prepared 48 hr posttransfection and results 083 HIV LTR DTAR and Gal4 Tat resulted in marked
shown represent values averaged from a single transfection performed apparent increases in abundance of both promoter-proxi-
in duplicate.
mal and promoter-distal transcripts (Fig. 7B; lane 6). The
ratios of promoter-distal to promoter-proximal transcripts
from G6 083 HIV LTR DTAR in the absence (1.0; laneto a DNA-binding domain and bound to sites within the
HIV-1 LTR (Berkhout et al., 1990; Southgate and Green, 4) or presence (0.98; lane 5) of Tat are approximately
equivalent (Fig. 7B). This ratio decreased in the presence1991; Kamine and Chinnadurai, 1992; Ghosh et al., 1993).
Although initiation effects of Tat have been reported, of Gal4 Tat. These data indicated that TAR-independent
transactivation by Tat requires intact kB enhancer ele-most observations collectively demonstrate that Tat func-
tions during HIV-1 transcriptional elongation (Laspia et ments within the HIV-1 LTR. Although not directly tested,
these experiments suggested that Tat and Gal4 Tat areal., 1989; Marciniak and Sharp, 1991; Marciniak et al.,
1990a; Rittner et al., 1995; Adams et al., 1994). To investi- capable of functioning at the level of transcription initia-
tion and elongation during TAR-independent transactiva-gate the predominant mode of transcriptional stimulation
during TAR-independent transactivation by Tat in tion of HIV-1 gene expression in glial cells. Notably, and
as indicated by comparing the ratios of promoter-distalastrocytic glial cells, ribonuclease protection assays
were performed to determine the relative abundance of to proximal transcripts in the absence and presence of
Tat, the effect of Tat on transcription initiation was signifi-promoter-proximal and promoter-distal transcripts from
HIV-1 LTR reporters containing or lacking kB enhancer cantly greater than its effect on elongation.
The results presented above suggested that Tat trans-elements. The ratio of distal to proximal transcripts pro-
vides an assessment of the efficiency of transcription activates the HIV-1 LTR in the absence of TAR predomi-
nantly at the level of transcription initiation in glial cells.elongation versus transcription initiation.
To detect promoter-proximal transcripts, an antisense To compare this mode of regulation to TAR-dependent
transactivation in glial cells, promoter-proximal and -dis-RNA probe was generated to protect a 100-nt fragment
spanning nucleotides immediately downstream of the tal transcripts generated from an HIV-1 promoter tem-
plate containing TAR in U87-MG cells were analyzedtranscription initiation start site at /1 and including 63
nt of the CAT coding sequences (Fig. 7A). To detect pro- by similar ribonuclease protection assays. A promoter-
proximal antisense probe was prepared to detect a 83-moter-distal transcripts, an antisense RNA probe was
synthesized to hybridize to a 536-nt CAT gene fragment nt transcript (/1 to /83) (Fig. 7C). Analyses of cyto-
plasmic RNA from U87-MG cells cotransfected with0119(/289 to /825) relative to /1 in the CAT coding se-
quences (Fig. 7A). Transcripts generated from HIV-1 LTR HIV LTR CAT or 083 HIV LTR CAT and 12S.FS or Tat
expression vectors revealed that Tat increases the rela-reporters containing (G60119 HIV LTR DTAR) or lacking
(G6 083 HIV LTR DTAR) kB sites in the absence or tive abundance of distal to proximal transcripts in the
presence of TAR (Fig. 7D). This effect of Tat is enhancedpresence of Tat were analyzed quantitatively with both
promoter-proximal and -distal probes by ribonuclease upon deletion of sequences upstream of 083 (Fig. 7D;
compare lanes 2 and 4). These results suggest that, inprotection assays. The data suggested that Tat and Gal4
Tat increased the apparent abundance of both promoter- the presence of TAR, Tat transactivates HIV-1 transcrip-
tion predominantly at the level of elongation.proximal (100 nt) and promoter-distal (536 nt) transcripts
from G6 0119 HIV LTR DTAR (Fig. 7B), possibly indicat- RNase protection analyses performed in HeLa cells
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FIG. 7. (A) Schematic representation of promoter-proximal and -distal antisense riboprobes and respective protected fragments from ribonuclease
protection analyses of transcripts generated in the absence of TAR in U87-MG cells. Riboprobes were generated as described under Materials
and Methods to protect a 100-nt promoter-proximal and a 536-nt promoter-distal transcript generated from the HIV LTR DTAR reporters in ribonuclease
protection assays. The distal antisense riboprobe was used, as well, in ribonuclease protection assays of transcripts generated from HIV LTR CAT
reporters with intact TAR elements (data presented in D and E). Relative nucleotide map sites are indicated. (B) TAR-independent effects of Tat on
promoter-proximal and promoter-distal HIV-1 transcription in U87-MG cells. Ribonuclease protection analyses were performed on cytoplasmic RNAs
isolated from U87-MG cells transfected with G6 0119 HIV LTR DTAR or G6 083 HIV LTR DTAR reporter constructs (5 mg) in the absence
(pCMV12S.FS; 0.1 mg) or presence (pCMVTat or pGal4 Tat; 0.1 mg) of Tat. Cytoplasmic RNAs were extracted 36 hr posttransfection and analyzed
with promoter-proximal and promoter-distal riboprobes generated as described under Materials and Methods. The 536-nt promoter-distal protected
transcripts and the 100-nt promoter-proximal protected transcripts are indicated by arrows. The relative abundance of promoter-distal to promoter-
proximal protected transcripts generated from each promoter was calculated as a ratio. The values were normalized for the number of U residues
within respective protected fragments. The ratio of amounts of promoter-distal to promoter-proximal transcripts from each promoter in the presence
of the control vector, pCMV12S.FS, was arbitrarily set at a value of 1 and values obtained in the presence of Tat or Gal4 Tat were compared to
this basal value. (C) Schematic representation of promoter-proximal riboprobe and protected fragment from ribonuclease protection analyses of
transcripts generated in the presence of TAR in U87-MG cells. The riboprobe was generated as described under Materials and Methods to protect
an 83-nt promoter-proximal transcript from the HIV LTR reporters in ribonuclease protection assays. Relative nucleotide map sites are indicated.
(D) TAR-dependent effects of Tat on promoter-proximal and promoter-distal HIV-1 transcription in U87-MG cells. Ribonuclease protection analyses
were performed on cytoplasmic RNAs isolated from U87-MG cells transfected with 0119 HIV LTR CAT or 083 HIV LTR CAT reporter constructs (5
mg) in the absence (pCMV12S.FS; 0.1 mg, lanes 1 and 3) or presence (pCMVTat; 0.1 mg, lanes 2 and 4) of Tat. Cytoplasmic RNAs were extracted
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demonstrated increases in both promoter-proximal TAR-dependent transactivation in HeLa cells function
well during TAR-dependent transactivation in glial cells,and -distal protected transcripts (Fig. 7E); however, the
relative abundance of promoter-distal to promoter-prox- suggesting that TAR-dependent transactivation by Tat ex-
hibits cell-type specificity. Previous reports suggest thatimal transcripts decreased in the presence of Tat. This
effect was more notable when basal transcriptional lev- Tat mutants, including Cys22, Cys31, His33, Gln35, and
Lys41 have reduced transactivational activity in nonglialels of elongation-competent transcripts were reduced
as is observed in the absence of sequences upstream cells that correlates with significantly destabilized struc-
tures as determined by protease digestion studies (Riceof 083 (Fig. 7E; compare lanes 1 and 3). A similar effect
has been observed in vitro (Bohan et al., 1992). and Carlotti, 1990a). From the glial cell studies presented
herein, Cys31, His33, and Lys41 have high TAR-indepen-Collectively, these data suggest alternative regulatory
pathways for Tat transactivation in glial cells where Tat dent transactivational activities; Cys22, Cys31, His33,
Gln35, and Lys41 have high TAR-dependent transactiva-predominantly activates HIV-1 transcription initiation in
the absence of TAR and transcription elongation in the tional activities. In glial cells, therefore, destabilized
structural patterns, as indicated by protease sensitivitypresence of TAR. TAR-dependent transactivation is ob-
served whether kB enhancer elements are present or or resistance previously described failed to predict trans-
activational capacity of these Tat mutants. Interestingly,absent within the HIV-1 LTR, while TAR-independent
transactivation requires these elements. high frequencies of functionally defective tat genes have
been identified (Meyerhans et al., 1989) and a single
amino acid change in Tat may result in differential effectsDISCUSSION
on the rate of HIV-1 replication (Leguern et al., 1993). A
transdominant Tat mutant, Cys22, has been shown toResults from transient expression assays using HIV-1
accelerate progression to latency and to inhibit HIV-1LTR CAT or HIV LTRDS CAT reporter constructs in the
reactivation from latency (Balboni et al., 1993). Thesepresence or absence of wild-type or mutant Tat expres-
data collectively propose that the ability of Tat to trans-sion vectors demonstrate that HIV-1 Tat exerts differen-
activate HIV-1 gene expression in both TAR-independenttial effects on TAR-independent and TAR-dependent
and TAR-dependent manners through alternative regula-transactivation. Site-directed mutagenesis studies iden-
tory pathways may complicate the use, and the poten-tify discrete functional domain differences within the cys-
tially the efficacy, of anti-HIV-1 therapies that target TARteine-rich region of Tat required for TAR-independent and
(TAR RNA decoys) or Tat (transdominant Tat mutants).TAR-dependent transactivation. A glycine substitution
Transient expression assays utilizing 5*-truncated HIV-mutant, Cys22, and an alanine substitution mutant,
1 LTR constructs show that two tandem-repeat kB sitesGln35, significantly reduce TAR-independent transactiva-
located between 0119 and 083 relative to the transcrip-tion (50%) compared to wild-type Tat activity. Other ala-
tion initiation start site (/1) are responsive to Tat trans-nine substitution mutants (Thr23, Asn24, Tyr26, Lys2829,
activation and that sequences between 083 and 069His33, and Lys41), a glycine substitution mutant (Cys31),
(third Sp1 site) are required for Gal4 Tat-mediated trans-and a truncation mutant (D57) possess high transactiva-
activation in the absence of TAR in an astrocytic glialtional activities, similar to that of wild-type Tat. Among the
cell line. Previous reports provide a model in which Tatpanel of Tat mutants tested, only an alanine substitution
is bound by an adapter molecule that brings NF-kB intomutant, Tyr26, has lower transactivational activity (50%
the transcription initiation complex. The adapter activitycompared to wild-type Tat activity) in the presence of
is particularly rich in astrocytic cells and in stimulated TTAR. Other mutants have wild-type levels of activity.
lymphocytes (Taylor et al., 1995). Also, recent studiesThese data indicate that HIV-1 Tat operates through dis-
show that extracellular HIV-1 Tat protein is associatedcrete mechanisms to support different modes of trans-
activation in glial cells. Further, Tat mutants impairing with an increase in NF-kB binding in primary human
36 hr posttransfection and analyzed with a promoter-proximal(C) and promoter-distal (A) antisense probe. The 83-nt promoter-proximal and 536-nt
promoter-distal protected fragments are indicated by arrows. The relative abundance of promoter-proximal and -distal protected transcripts was
normalized for the number of m residues within the protected fragments. The relative abundance of promoter-distal to -proximal protected transcripts
generated from each promoter was calculated as a ratio. The ratio of amounts of promoter-distal to -proximal transcripts from each promoter in
the presence of the control vector, pCMV12S.FS, was arbitrarily set at a value of 1 and the ratio obtained in the presence of Tat was compared to
this basal value. (E) TAR-dependent effects of Tat on promoter-proximal and promoter-distal HIV-1 transcription in HeLa cells. Ribonuclease protection
analyses were performed on cytoplasmic RNAs isolated from HeLa cells transfected with 0119 HIV LTR CAT or083 HIV LTR CAT reporter constructs
(5 mg) in the absence (pCMV12S.FS; 0.1 mg, lanes 1 and 3) or presence (pCMVTat: 0.1 mg, lanes 2 and 4) of Tat. Cytoplasmic RNAs were extracted
36 hr posttransfection and analyzed with a promoter-proximal (C) and promoter-distal (A) antisense probe. The 83-nt promoter-proximal and 536-nt
promoter-distal protected fragments are indicated by arrows. The relative abundance of promoter-proximal and -distal protected transcripts was
normalized for the number of U residues within the protected fragments. The relative abundance of promoter-distal to -proximal protected transcripts
generated from each promoter was calculated as a ratio. The ratio of amounts of promoter-distal to -proximal transcripts from each promoter in
the presence of the control vector, pCMV12S.FS, was arbitrarily set at a value of 1 and the ratio obtained in the presence of Tat was compared to
this basal value.
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astrocytes (Conant et al., 1996). Here, and consistent 1996; Okamoto et al., 1996) with only minimal, if any,
effects during initiation. RNA polymerase II transcriptionwith these reports, data suggest that Tat may be tethered
to the transcription initiation complex, directly or indi- complexes have been categorized into two classes:
poorly processive and processive transcription com-rectly, through upstream kB elements or Gal4 Tat DNA-
binding sites placed naturally or synthetically within the plexes. Poorly processive complexes, which lack the
general transcription factors TFIIE and TFIIH, initiateHIV-1 LTR in the absence of TAR.
Efficient Tat activation of HIV-1 transcription requires transcription, then pause and halt within promoter-proxi-
mal regions leading to prematurely terminated tran-Tat and cellular transcription factors (e.g., Sp1) (Harrich
et al., 1989; Kamine and Chinnadurai, 1992; Jeang et al., scripts. Processive transcription complexes that include
a complete assembly of transcription factors generate1993; Sune and Garcia-Blanco, 1995) and upstream regu-
latory proteins such as NF-kB (Liu et al., 1992; Perkins et full-length RNA. The general transcription factors TFIIE
and TFIIH are not required for transcription initiation, butal., 1993). Sp1 interacts directly with Tat in vitro and in
vivo (Jeang et al., 1993) and also binds specifically to the are necessary for releasing paused complexes from the
promoter (Krumm et al., 1995). The ability of Tat to stimu-TATA box-binding protein, TBP (Emili et al., 1994). Sp1
may facilitate the formation of HIV-1 transcription initiation late the activity of a TFIIH-associated kinase and resul-
tantly affect Pol II CTD phosphorylation may be a criticalcomplexes that are responsive to Tat (Smale et al., 1990;
Kamine et al., 1991; Zhou and Sharp, 1995; Rittner et al., regulatory mechanism whereby Tat increases the pro-
cessivity of HIV-1 transcription complexes (Parada and1995). Substitution of binding sites for Sp1 with those for
other DNA sequence-specific transcription factors such Roeder, 1996). Another transcription factor, P-TEF (posi-
tive transcription elongation factor), which is sensitive toas ATF, USF, or AP-1, leads to a significant level of trans-
activation by Tat (Southgate and Green, 1991; Berkhout DRB (5,6-dichloro-1-b-D-ribofuranosyl benzimidazole), a
compound that is used to study transcription in vivo andand Jeang, 1992; Madore and Cullen, 1995).
The functional TATA element of the HIV-1 promoter has in vitro, may be added to paused HIV-1 transcriptional
complexes to generate productive elongation complexesbeen shown to be important in the initiation steps of Tat
transactivation (Berkhout and Jeang, 1992; Lu et al., 1993; (Marshall and Price, 1992). The transcription factor, TFIIF,
which binds to RNA polymerase II and stimulates theRittner et al., 1995). Basal promoter elements including
the TATA element can mediate differential regulatory ef- rates of polymerization and promoter clearance, acts as
a processivity factor for polymerase complexes throughfects by various transcription effectors (Das et al., 1995).
From the data presented herein, different promoter-proxi- suppression of pausing. Tat has been documented to
act with TFIIF to stimulate transcription elongation (Katomal effectors including Gal4 Sp1, Gal4 Sp1Q, Gal4 AH,
Gal4 RegI, Gal4 RegII, Gal4 Vp16, and Gal4 RelA fail to fully et al., 1992; Chang et al., 1993). The generation of full-
length RNA requires de novo initiation in which distinctrestore wild-type Tat activity on a basal HIV-1 promoter in
the absence of TAR (G6 031 HIV LTR DTAR). These re- promoter elements necessary for efficient elongation of
transcription recruit factors to generate initiation or earlysults indicate that glutamine-rich activation domains (Gal4
Sp1 and Gal4 Sp1Q), acidic activation domains (Gal4 AH, elongation complexes. Studies have found that transcrip-
tion from the HIV-1 LTR in the absence of Tat results inGal4 RegI, Gal4 RegII, and Gal4 Vp16), and Gal4 RelA
cannot substitute for NF-kB-binding sites during TAR-inde- an abundance of specific-length, short transcripts con-
taining the TAR sequence that forms a stable stem-and-pendent transactivation by Tat. Hence, kB sites are re-
quired for full transactivation of HIV-1 LTR-directed gene loop structure. Some studies suggest that these short
RNAs are generated from abortive transcription (Marshallexpression in the absence of TAR in astrocytic glial cells.
Constitutive expression of a transdominant repressor mu- and Price, 1992) and that they accumulate in cells to
sequester Tat during the latent stages of HIV-1 infection.tant of IkBa in U87-MG cells inhibits TAR-independent
transactivation by Tat, suggesting that Tat transcriptional The IST element (inducer of short transcripts) is involved
in the synthesis of premature short RNAs. IST is a consti-activity in the absence of TAR requires a functional IkBa-
regulated NF-kB complex. tutively active, nonprocessive promoter element within
HIV-1 LTR (between 05 and /26) that structurally differsHIV-1 Tat facilitates early stages of HIV-1 transcription
preinitiation complex formation in vitro (Bohan et al., from the inducible, processive promoter element. Inacti-
vation of IST impedes the formation of nonprocessive1992). Also, Tat increases the rate of transcription of the
first 24 nt of the HIV-1 leader region and affects the initiation complexes (Ratnasabapathy et al., 1990; Shel-
don et al., 1993).polarity of transcription. These results suggest an effect
of Tat during transcription initiation (Laspia et al., 1989). A main objective of the study presented here was to
determine the predominant level at which Tat transacti-In most studies, however, Tat predominantly executes its
activity during transcription elongation (Laspia et al., vates HIV-1 transcription in the absence and presence
of TAR in U87-MG cells. In these studies, Tat was deter-1989, 1993; Marciniak and Sharp, 1991; Kato et al., 1992;
Kessler and Mathews, 1992; Cullen, 1993; Adams et al., mined to stimulate HIV-1 LTR-directed gene expression
in the absence of TAR by affecting predominantly tran-1994; Garcia-Martinez et al., 1995; Bentley, 1995; Rittner
et al., 1995; Mavankal et al., 1996; Parada and Roeder, scription initiation, as the relative abundance of pro-
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moter-distal to -proximal transcripts generated in the all rate of gene expression is apparently reduced. As
indicated by the studies herein, TAR-independent trans-presence of Tat was less than that observed in the ab-
sence of Tat. The opposite effect was observed in the activation by Tat exhibits strict cell-type specificity. Eluci-
dating the qualitative and/or quantitative differences inpresence of TAR, suggesting a predominant effect of Tat
during TAR-dependent transactivation at the level of tran- HIV-1 transcription complexes that form on nascent or
TAR-deleted HIV-1 promoters in glial- and nonglial-de-scription elongation. These findings differ from those
published previously in which the transcriptional effects rived cells may provide insight into the molecular mecha-
nisms that underlie alternative regulatory pathways uti-of Tat in U87-MG cells appeared to be due to an increase
in transcription initiation in both the presence and the lized by Tat during the pathogenesis of AIDS.
absence of TAR (Niikura et al., 1996). Data presented
here demonstrated further that Tat required the presence ACKNOWLEDGMENTS
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